PTK 2015 Banner 
2015 Peptalk M Banner 

Pipeline One Icon Pipeline One Header 

Cambridge Healthtech Institute’s 2nd Annual
Enhancing Antibody Binding and Specificity
Emerging Science and New Technologies to Fine-
Tune Antibody-Antigen Binding and Target Specificity

January 21-22, 2015


As the industry expands its repertoire of antibody drug products into new therapeutic areas, product formats and protein constructs, the control of antibody/antigen targeting, binding and specificity take on a new level of importance for researchers in this field. The second component of the PepTalk Protein Engineering & Development pipeline, Enhancing Antibody Binding and Specificity, presents innovative approaches to the modulation of binding activity, mechanism of action and difficult target challenges such as transmembrane proteins.

Preliminary Agenda 


SPECIFICITY ENGINEERING  


KEYNOTE PRESENTATION 

The Impact of Anti-IgG Hinge Antibodies in Protease-Enriched Diseases

Robert E. Jordan, Ph.D., Senior Director and Senior Research Fellow, (retired) Janssen Pharmaceuticals

Engineering of High Affinity Two-in-One Antibodies Using Phage Display Coupled to Deep Sequencing

Sarah Sanowar, Ph.D., Senior Research Associate, Antibody Engineering, Genentech, a Member of the Roche Group


STRATEGIES FOR SCREENING LARGE ANTIBODY LIBRARIES  

The Antibiome: Toward Renewable Antibodies to the Proteome

Michael Hornsby, Ph.D., Researcher, Pharmaceutical Chemistry, University of California, San Francisco

Pipeline 2.0: Integrating All Aspects from Target Acquisition through Binder Validation for Optimized Binder Generation

Jonas V. Schaefer, Ph.D., Head, High-Throughput Laboratory, Department of Biochemistry, University of Zurich


SCREENING FOR RARE ANTIBODIES  

An in vivo Human-Plasmablast Enrichment Technique Allows Rapid Identification of Therapeutic Influenza A Antibodies

Lee Swem, Ph.D, Scientist, Infectious Disease Group, Genentech, a Member of the Roche Group

Towards a Quantum Leap in the Utility of Combinatorial Libraries for Drug Hunters by Placing New Functional Screening Options Up Front

Ronald M. Lindsay, Ph.D., CEO, Zebra Biologics


RATIONAL APPROACHES TO ANTIBODY ENGINEERING  

Antibody Modeling and Computational Design of Optimized Molecules

Stanley Krystek, Ph.D., Senior Principal Scientist, Bristol-Myers Squibb

Extracting Life's Operating Manual–Comprehensive Ruleset Discovery and Bioengineering Applications

Jacob Glanville, Ph.D., CSO, Distributed Bio

Precise and Efficient Antibody Epitope Determination through Library Design, Yeast Surface Display and Next-Generation Sequencing

Thomas Van Blarcom, Ph.D., Principal Scientist, Protein Engineering, Pfizer, Inc.


DISCOVERY AND DEVELOPMENT OF ANTIBODIES FOR MEMBRANE PROTEIN TARGETS  

GPCR Expression by Individual Cell Types: Novel Membrane Targets for Therapeutic Antibodies

Paul Insel, Ph.D., Professor, Pharmacology & Medicine, University of California, San Diego

Targeting T-Cells with an Anti-Ion Channel Antibody with Ultralong CDR H3s

Vaughn Smider, M.D., Ph.D., Assistant Professor, Molecular Biology, The Scripps Research Institute

Molecular Snapshot of GPCR Regulation and Signaling by Arrestins: Emerging Avenues for Novel Drug Discovery

Arun Shukla, Ph.D., Professor, Medicine, Duke University Medical Center

Discovery and Optimization of Novel Functional Anti G-Protein Coupled Receptor Monoclonal Antibodies

Trevor Wilkinson, Ph.D., Associate Director, Protein Sciences, Antibody Discovery and Protein Engineering, MedImmune

High-Throughput Strategies to Obtain High Affinity, Specific, and Conformationally Selective Recombinant Antibodies to Membrane Proteins by Phage Display

Marcin Paduch, Ph.D., Technical Director, Synthetic Antibody & Crystallography Core Facility, The University of Chicago